awmsg logo



trastuzumab (Herceptin®)


Reference No. 1066

Publication date:
18/05/2012


Appraisal information

trastuzumab (Herceptin®) powder for concentrate for solution for infusion


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 04/01/2012
AWMSG meeting date: 08/02/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0312
Ministerial ratification: 16/05/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Trastuzumab (Herceptin®) is recommended as an option for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. This submission covers the licence extensions for treatment with trastuzumab: • following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; • in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. AWMSG is of the opinion that trastuzumab (Herceptin®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download